Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”

Published 2023 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-11-01
DOI
10.1002/ijc.34786
References
View 2 related references

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.